European Society of Cardiology guidelines recommend the implementation of dual antiplatelet therapy (DAPT) for 12 months, angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), beta-blockers and statins [1] in patients after myocardial infarction (MI). The gene discussed is ACE; the disease is myocardial infarction.